Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to <scp>iGlarLixi</scp> : A participant‐level pooled analysis of three phase 3 <scp>LixiLan</scp> randomized controlled trials
iGlarLixi achieved improvements in dTIR, with low dTBR values, providing further evidence to inform clinical outcomes with the use of iGlarLixi.
Authors
- Alice Cheng (ORCID: https://orcid.org/0000-0003-2729-606X)
- Felipe Lauand
- Martin Haluzı́k (ORCID: https://orcid.org/0000-0002-0201-6888)
- Julio Rosenstock (ORCID: https://orcid.org/0000-0001-8324-3275)
- Lydie Melas‐Melt (ORCID: https://orcid.org/0000-0001-9698-8196)
- Mohammed E. Al‐Sofiani (ORCID: https://orcid.org/0000-0003-4420-9378)
Institutions
- Johns Hopkins University (US)
- University of Toronto (CA)
- King Saud University (SA)
- Sanofi (France) (FR)
- Institute of Clinical and Experimental Medicine (CZ)
- Velocity Clinical Research (United States) (US)
- Arysta LifeScience (France) (FR)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-09-08
- DOI
- https://doi.org/10.1111/dom.15811
- Citations
- 2
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- Sanofi